FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1449PDF: 309HTML: 206Supplementary: 103 -
Anticoagulation in obese patients: challenges and strategies
2037PDF: 537HTML: 306XML: 191 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1360PDF: 220HTML: 135Appendix: 120 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
754PDF: 26 -
CO-22 | CLINICAL FEATURES IN PATIENTS WITH NON-SEVERE HEMOPHILIA A: THE DISCOVERY SCORE PROPOSAL FOR PROPHYLAXIS PRESCRIPTION M.N.D. Di Minno1, E. Baldacci2, C. Biasoli3, A. Borchiellini4, F. Daniele5, P. Di Gregorio6, C. Gorio7, G. Malcangi8, E. Marchesini9, I. Ricca10, R. Santoro11, S. Siragusa12, M.R. Villa13, E. Zanon14, A. Tagliaferri15, A. Coppola15 | 1Hub Centre for Thrombotic and Hemorrhagic Disorders, Federico II University Hospital, Napoli, Italy; 2Haematology, University Hospital Policlinico Umberto I, Roma, Italy; 3Interdepartmental Simple Structure for the Management of Hemorrhagic and Thromboembolic Diseases, M. Bufalini Hospital, Cesena, Italy; 4Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 5Haemostasis and Thrombosis Service, Ospedale Civile dell'Annunziata, Cosenza, Italy; 6Transfusion Medicine Department, "SS. Annunziata" Hospital, Chieti, Italy; 7Pediatric Onco-Hematology Unit, Children's Hospital, ASST-Spedali Civili, Brescia, Italy; 8Haemophilia and Thrombosis Center, University Hospital Policlinico-Giovanni XXIII, Bari, Italy; 9Hemophilia Centre, SC Vascular and Emergency Department, University of Perugia, Italy; 10Centro Emofilia, Città della Salute e della Scienza, Torino, Italy; 11Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 12Centro di Riferimento Regionale per le Emocoagulopatie Congenite, Palermo, Italy; 13Hematology Unit, Ospedale Santa Maria di Loreto, Napoli, Italy; 14Hemophilia and Thrombosis Center, University Hospital of Padua, Italy; 15Hemophilia and Thrombosis Center, Azienda Ospedaliera di Parma, Italy
55PDF: 15 -
PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
573PDF: 24 -
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
576PDF: 15 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
925PDF: 120HTML: 129Supplementary: 79Appendix: 80 -
PO45 | Routine prophylaxis with PD-FX concentrate in severe inherited FX deficiency: a case report S. Linari, L. Pieri, M. Attanasio, F. Salvianti, M. Coppo, E. Grisanti, F. Demartis, R. Fjerza, G. Castaman | Centre for Bleeding Disorders and Coagulation, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
625PDF: 20 -
PO043 | MULTICENTRE REAL‑WORLD EXPERIENCE OF EMICIZUMAB PROPHYLAXIS IN AN ITALIAN COHORT OF 49 CHILDREN WITH SEVERE HEMOPHILIA A - EMIPED STUDY L. Pieri1, B. Pollio2, P. Giordano3, G. Lassandro4, S. Linari1, R. Pasquino1, E. Piellucci1, MC. Di Stefano1, F. Demartis1, R. Fjerza1, G. Castaman1 | 1Center for Bleeding Disorders, Careggi University Hospital, Firenze, Italy; 2Center for Inherited Bleeding and Thrombotic Disorders, Transfusion Medicine, "Regina Margherita" Children Hospital, Torino, Italy; 3Department of Interdisciplinary of Medicine, University of Bari 'Aldo Moro', Bari, Italy; 4General and Specialised Pediatrics Unit, "Giovanni XXIII" Hospital, University of Bari, Bari, Italy
27PDF: 8 -
CO-60 | A TURNING POINT IN THE MANAGEMENT OF HEMOPHILIA B WITH INHIBITORS: OUTCOMES OF CONCIZUMAB PROPHYLAXIS IN TWO CHILDREN FROM EXPLORER10 G. Quintavalle1, A. Matichecchia1, M.I. Tassoni1, B.M. Roccon1, F. Riccardi1, R.P. Serra2, A. Tiri2, P. Bertolini2, A. Tagliaferri1, A. Coppola1 | 1Regional Hub Center for Hemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Italy; 2Pediatric Hematology-Oncology Unit, University Hospital of Parma, Italy
45PDF: 16 -
CO-70 | CONGENITAL AFIBRINOGENEMIA: BLEEDING PHENOTYPE, THROMBOTIC COMPLICATIONS, AND LONG-TERM MANAGEMENT IN A MULTICENTER COHORT M. Biglietto1|2, M. Presti1, R.C. Santoro3, I. Nichele4, M. Napolitano5, S. Pasca6, A. Borchiellini7, B. Pollio8, E. Zanon9, G. Barillari10, A. Poz10, S. Sorella1, S. Ligia1, R. Mormile1, E. Baldacci1, G. Castaman11, F. Peyvandi12|13, C. Santoro1 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy; 2Department of Molecular Biology, Sapienza University of Rome, Italy; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy; 4Hematology Unit, Azienda ULSS 8 Berica - San Bortolo Hospital, Vicenza, Italy; 5Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy; 6Coagulation Diseases Center, Transfusion Medicine Department - Azienda Sanitaria Universitaria Integrata del Trentino, Trento, Italy; 7Centro di Riferimento Regionale Malattie Emorragiche e Trombotiche dell'Adulto, Divisione di Ematologia, Università Città della Salute e della Scienza di Torino, Italy; 8SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, A.O. Città della Salute e della Scienza, Torino, Italy; 9Department of Medicine, Haemophilia Centre, University Hospital of Padua, Italy; 10Center for Hemorrhagic and Thrombotic Diseases, General and University Hospital S. Maria della Misericordia, Udine, Italy; 11Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze, Italy; 12IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 13Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milano, Italy
43PDF: 16 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
668PDF: 29 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
511PDF: 96 -
CO-33 | REAL-WORLD EXPERIENCE WITH MARSTACIMAB PROPHYLAXIS IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS AND ADVANCED HEMOPHILIC ARTHROPATHY A. Casson1, I. Ricca1, A. Barchieri1, G. Guido1, M. Tucciarone1, P. Ocello1, C. Francisco2, P. Abrate2, G. Delios1 | 1Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Torino, Italy; 2SC Farmacia Ospedaliera ASL TO4, Ivrea, Torino, Italy
43PDF: 16 -
PO056 | SYNERGISTIC EFFECT OF RECOMBINANT FACTOR INFUSION ON THROMBIN GENERATION IN HEMOPHILIA PATIENTS UNDER EMICIZUMAB OR CONCIZUMAB PROPHYLAXIS F. Bocchi1|2, R. Pastorino1|2, M. Capetta1|2|3, S. Bergonzi1|2|3, G. Murante1|2|3, F. Valeri2|3, C. Dainese2|3, A. Valpreda4, B. Bruno1|3, A. Borchiellini2|3 | 1Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 2Regional Center for Thrombotic and Hemorrhagic Diseases; 3Division of Hematology; 4Central Lab Baldi and Riberi, AOU Città della Salute e della Scienza di Torino, Italy
23PDF: 8 -
CO-27 | INNOVATIVE USE OF EPTACOG BETA TO TREAT ACUTE ELBOW HEMARTHROSIS IN A PEDIATRIC PATIENT WITH HEMOPHILIA B AND A HISTORY OF INHIBITORS, UNDERGOING SECONDARY PROPHYLAXIS WITH CONCIZUMAB L. Laterza1, P. Giordano2, G. Lassandro2 | 1University of Bari "Aldo Moro", Interdisciplinary Department of Medicine, Bari, Italy; 2Pediatric Haemophilia Center-AOUC Pol. Giovanni XXXIII, University of Bari “Aldo Moro”, Bari, Italy
52PDF: 16 -
PO40 | Management of paediatric patients affected by mild factor VII deficiency undergoing surgery B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
572PDF: 12 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
566PDF: 24 -
CO-89 | FEMORAL FRACTURE SURGERY IN AN ELDERLY, FRAIL PATIENT WITH ACQUIRED HEMOPHILIA A RECEIVING EMICIZUMAB PROPHYLAXIS: A CASE REPORT C. Simion1|2, E. Zanon1|2, B. Stocco1|2, F. Sartorello1, C. Bulato1, G. Saggiorato1, P. Simioni1|2 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; 2Hemophilia Center, Padova University Hospital, Italy
42PDF: 19 -
CO-50 | LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND BLEEDING DISORDERS: A SINGLE-CENTER EXPERIENCE B.M. Roccon1, M.I. Tassoni1, G. Quintavalle1, G. Benatti2, F. Gurgoglione2, R. Rossi3, C. Cattabiani3, L. Vignali2, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SSD Cardiologia Interventistica, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Laboratorio di Coagulazione, UOC Patologia Clinica, Azienda Ospedaliero-Universitaria di Parma, Italy
51PDF: 18 -
BEST-04 | MAJOR ORTHOPEDIC SURGERY WITH EMICIZUMAB: A SERIES OF 22 PATIENTS (40 PROCEDURES) WITH A MID-TERM FOLLOW-UP G. Daniele1, C. Carulli1, S. Linari2, L. Pieri2, G. Castaman2 | 1Clinica Ortopedica, Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy; 2Centro Malattie Emorragiche e della Coagulazione, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
86PDF: 13 -
PO045 | FROM PROPHYLAXIS TO ENDOGENOUS CONTROL: A SIX-MONTH REAL-WORLD EXPERIENCE WITH VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY M. Basso1, A. Ferretti1, M. Sacco1, S. Lancellotti1, T. Pirozzi1, L. Di Gennaro1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
23PDF: 11 -
PO123 | PERIOPERATIVE MANAGEMENT OF FEMORAL FRACTURE SURGERY IN AN ELDERLY PATIENT WITH ACQUIRED HEMOPHILIA A RECEIVING EMICIZUMAB C. Simion, E. Zanon, B. Stocco, G. Saggiorato, F. Sartorello, C. Bulato, P. Simioni | Department of Medicine, University of Padova, Italy
20PDF: 8 -
CO-67 | CONGENITAL DYSFIBRINOGENEMIA: BLEEDING PHENOTYPE, THROMBOTIC COMPLICATIONS, AND LONG-TERM MANAGEMENT IN A MULTICENTER COHORT M. Biglietto1|2, M. Presti1, R.C. Santoro3, I. Nichele4, M. Napolitano5, S. Pasca6, A. Borchiellini7, B. Pollio8, E. Zanon9, G. Barillari10, A. Poz10, S. Sorella1, S. Ligia1, R. Mormile1, E. Baldacci1, G. Castaman11, F. Peyvandi12|13, C. Santoro1 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy; 2Department of Molecular Biology, Sapienza University of Rome, Italy; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy; 4Hematology Unit, Azienda ULSS 8 Berica - San Bortolo Hospital, Vicenza, Italy; 5Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy; 6Coagulation Diseases Center, Transfusion Medicine Department - Azienda Sanitaria Universitaria Integrata del Trentino, Trento, Italy; 7Centro di Riferimento Regionale Malattie Emorragiche e Trombotiche dell'Adulto, Divisione di Ematologia, Università Città della Salute e della Scienza di Torino, Italy; 8SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, A.O. Città della Salute e della Scienza, Torino, Italy; 9Department of Medicine, Haemophilia Centre, University Hospital of Padua, Italy; 10Center for Hemorrhagic and Thrombotic Diseases, General and University Hospital S. Maria della Misericordia, Udine, Italy; 11Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze, Italy; 12IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 13Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milano, Italy
46PDF: 13 -
BEST-08 | PERIOPERATIVE MANAGEMENT OF CHILDREN WITH MILD FACTOR VII DEFICIENCY UNDERGOING SURGERY: A RETROSPECTIVE COHORT STUDY B. Borsellino1, T. Martini1, I. Ricca2, B. Pollio1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Transfusion Medicine, Ivrea Hospital, Ivrea, Italy
93PDF: 15 -
CO-62 | ACCESS TO ULTRA-LONG HALF-LIFE FACTOR VIII AS THE DEFINITIVE MOTIVATION FOR IMMUNE TOLERANCE INDUCTION IN THE ERA OF NON-REPLACEMENT THERAPIES B. Borsellino1, T. Martini1, I. Ricca2, C. Linari3, B. Pollio1 | 1Paediatric Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital "Città della Salute e della Scienza", Torino, Italy; 2Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; 3Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy
39PDF: 12 -
BEST-05 | LONG-TERM EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: REAL-WORLD EXPERIENCE ACROSS ALL AGES A. Colombo1, I. Quaglia1, M.R. Fasulo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
93PDF: 14 -
PO064 | CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA: HOW TO MANAGE? - A CASE FROM REAL WORLD N. Galli1, S. Giuliano2, S. Grasso3, B. Montaruli4, D. Cilloni1, G. Giuffrida3, P. Sivera4 | 1Department of Clinical and Biological Sciences, University of Turin, Italy; 2Department of Medical Sciences, University of Turin, Italy; 3AOU Policlinico “G. Rodolico San Marco”, Catania, Italy; 4Haematology and Cellular Therapies Unit, A. O. Ordine Mauriziano di Torino, Italy
23PDF: 9 -
CO-47 | JOINT ULTRASOUND FOLLOW-UP IN PEDIATRIC PATIENTS WITH HEMOPHILIA: A 12-YEAR PROSPECTIVE SINGLE-CENTER EXPERIENCE I. Ricca1, B. Borsellino2|3, T. Martini2, C. Martinoli4, B. Pollio2 | 1Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; 2Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 3Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy; 4Department of Health Science DISSAL, University of Genova, Unit of Radiology and IRCCS San Martino Hospital, Genova, Italy
50PDF: 17 -
CO-28 | SYNERGISTIC EFFECT OF RECOMBINANT FACTOR INFUSION ON THROMBIN GENERATION IN HEMOPHILIA PATIENTS UNDER EMICIZUMAB OR CONCIZUMAB PROPHYLAXIS F. Bocchi1|2, R. Pastorino1|2, G. Murante1|2|3, S. Bergonzi1|2|3, M. Capetta1|2|3, F. Valeri2|3, C. Dainese2|3, A. Valpreda4, B. Bruno1|3, A. Borchiellini2|3 | 1Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 2Regional Centre for Thrombotic and Hemorrhagic Diseases, AOU Città della salute e della Scienza di Torino, Italy; 3Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 4Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Italy
49PDF: 21 -
CS05 | Joint ultrasound follow-up in pediatric patients with haemophilia: a 12-year prospective single-center experience B. Borsellino1,2, B. Pollio1, C. Martinoli3, T. Martini1, R. Albiani1, I. Ricca1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma; 3Department of Health Science DISSAL, University of Genoa, Unit of Radiology and IRCCS San Martino Hospital, Genoa, Italy
683PDF: 28 -
CO-36 | PLATELETS MATTER: THROMBIN GENERATION IN PLATELET‐RICH-PLASMA VS. PLATELET‐POOR‐PLASMA UNDER NON-REPLACEMENT THERAPIES IN HEMOPHILIA F. Bocchi1|2, R. Pastorino1|2, G. Murante1|2|3, S. Bergonzi1|2|3, M. Capetta1|2|3, F. Valeri2|3, C. Dainese2|3, A. Valpreda4, B. Bruno1|3, A. Borchiellini2|3 | 1Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 2Regional Centre for Thrombotic and Hemorrhagic Diseases, AOU Città della salute e della Scienza di Torino, Italy; 3Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 4Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Italy
47PDF: 14 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
651PDF: 22 -
PO75 | Prophylaxis with RFXIII: a clinical case in a pediatric patient with congenital FXIII deficiency and delayed diagnosis M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione. Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
660PDF: 32 -
PO30 | Acquired angioedema associated with B-non Hodgkin lymphoma: a case report A. Pozzi, G. Rosati, S. Pizzimenti, M. Padrini, S. Laurenti, G. Ferrari, R. M. Medici, C. Barale, I. Russo, A. Morotti | Univeristy of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
584PDF: 30 -
CO27 | Intracerebral hemorrhage in hemophilia A and B: a 10-year prospective multicenter study in Italy (2012–2022) E. Zanon1, A. Napolitano1, A. Porreca2, F. Demartis3, A. Coppola4, C. Santoro5, I. Cantori6, A. C. Molinari7, C. Biasioli8, M. Luciani9, G. Sottilotta10, B. Pollio11, A. Borchiellini12, A. Tosetto13, P. Flora14, P. Simioni1 | 1Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua; 2Department of Human Sciences and Promotion of the Quality of Life, Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele Roma Open University, Roma; Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele, Roma; 3Centre for Bleeding Disorders, Careggi University Hospital of Firenze; 4Azienda Ospedaliero Universitaria di Parma; 5Hematology Division, Umberto I University Hospital of Roma; 6Haemophilia Center, Department of Transfusion Medicine, Hospital of Macerata; 7IRCCS Istituto Giannina Gaslini, Genova; 8Haemophilia and Transfusion Centre, Bufalini Hospital, Cesena; 9Children’s Hospital Bambino Gesù, Roma; 10Haemophilia Center, Department of Onco-Hematology and Radioterapy, Hospital of Reggio Calabria; 11Haemophilia Pediatric Center, Transfusion Medicine, City of Health and Science of Turin; 12City of Health and Science of Turin; 13Hemorrhagic and Thrombotic Diseases Unit, S. Bortolo Hospital of Vicenza; 14RCCS Foundation Ca’ Granda Maggiore Policlinico Hospital, Milan, Italy
692PDF: 31 -
CO-44 | EVALUATION OF THE DEVIATION BETWEEN PRESCRIBED AND RECOMMENDED EMICIZUMAB DOSING IN PATIENTS WITH CONGENITAL HEMOPHILIA A A.C. Giuffrida1, S. Abeysinghe Gunawardhana1, S. Amato2, F. Casoli2, C. Recchi2, M. Saggioro2, E. Bonetti3, M. Bodini1, G. Poli2 | 1Centro Emofilia, UOC Medicina Trasfusionale, AOUI Verona, Italy; 2UOC Laboratorio Analisi, AOUI Verona, Italy; 3UOC Oncoematologia Pediatrica, AOUI Verona, Italy
44PDF: 14 -
CO-13 | USE OF THE MULTIDIMENSIONAL HEMOPHILIA PAIN QUESTIONNAIRE IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH EMICIZUMAB: A PILOT CROSS-SECTIONAL, SINGLE-CENTER STUDY I.L. Calcaterra, S. Donnarumma, G. D’Errico, C. De Luca, C. Caputo, P. Ciciola, E. Cimino, M. Di Minno | Università Federico II di Napoli, Italy
85PDF: 15 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
625PDF: 22 -
CO-41 | COMPARISON OF COAGULATION AND CHROMOGENIC METHODS IN PHARMACOKINETICS WITH EXTENDED HALF-LIFE FACTOR VIII R. Pastorino1|2, F. Bocchi1|2, G. Murante1|2|3, S. Bergonzi1|2|3, M. Capetta1|2|3, F. Valeri2|3, C. Dainese2|3, A. Valpreda4, B. Bruno1|3, A. Borchiellini2|3 | 1Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 2Regional Centre for Thrombotic and Hemorrhagic Diseases, AOU Città della salute e della Scienza di Torino, Italy; 3Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 4Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Italy
39PDF: 14 -
CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY M. Biglietto, B. Mandelli, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, S. Truglia, C. Santoro | Sapienza, University of Rome, Italy
41PDF: 7 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
517PDF: 123 -
PO021 | PLATELETS MATTER: THROMBIN GENERATION IN PLATELET‐RICH PLASMA VERSUS PLATELET-POOR-PLASMA UNDER NON-REPLACEMENT THERAPIES IN HAEMOPHILIA F. Bocchi1|2, R. Pastorino1|2, G. Murante1|2|3, S. Bergonzi1|2|3, M. Capetta1|2|3, F. Valeri2|3, C. Dainese2|3, A. Valpreda4, B. Bruno1|3, A. Borchiellini2|3 | 1Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy; 2Regional Centre for Thrombotic and Hemorrhagic Diseases; 3Division of Hematology; 4Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Torino, Italy
21PDF: 10 -
CO-39 | MYELOID CELL FUNCTION AND CYTOKINE PROFILES IN PEDIATRIC HEMOPHILIA A: INSIGHTS FROM FACTOR VIII AND EMICIZUMAB PROPHYLAXIS T. Martini1, A. Cottonaro2, S. Akula2, B. Pollio1, I. Ricca3, J. Agnelli Giacchello4, P. Sciancalepore4, R. Santi4, A. Follenzi2|4, S. Merlin2 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy; 3Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; 4Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
53PDF: 13 -
CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
676PDF: 12 -
PO146 | COMPARISON OF COAGULATION AND CHROMOGENIC METHODS IN PHARMACOKINETICS WITH EXTENDED HALF-LIFE FACTOR VIII R. Pastorino1|2, F. Bocchi1|2, G. Murante1|2|3, S. Bergonzi1|2|3, M. Capetta1|2|3, F. Valeri2|3, C. Dainese2|3, A. Valpreda4, B. Bruno1|3, A. Borchiellini2|3 | 1Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy; 2Regional Centre for Thrombotic and Hemorrhagic Diseases; 3Division of Hematology; 4Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Torino, Italy
23PDF: 9 -
CO-66 | PREGNANCY OUTCOMES AND PERIPARTUM MANAGEMENT IN WOMEN WITH CONGENITAL FIBRINOGEN DISORDERS: A SINGLE-CENTRE EXPERIENCE T. Martini1, B. Borsellino1|2, B. Pollio1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
42PDF: 14 -
PO040 | PHARMACODYNAMIC CHARACTERIZATION OF THROMBIN GENERATION IN SEVERE HEMOPHILIA A PATIENTS ON EMICIZUMAB PROPHYLAXIS: A REAL-WORLD LONGITUDINAL STUDY M. Bergamaschi, A. Pallotta, M. Biglietto, S. Sorella, S. Ligia, E. Baldacci, A. Chistolini, C. Santoro, R. Mormile | Department of translational and precision Medicine, Sapienza, University of Rome, Italy
24PDF: 8 -
PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing L. Torrieri, S. Ligia, E. Baldacci, R. Mormile, S. Sorella, R. Ciciani, M. Biglietto, N. Zhdanovskaya, A. Delli Paoli, A. Tirnetta, M. Lorenzon, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
633PDF: 13 -
CO-49 | JOINT STATUS EVALUATION BY ULTRASOUND AND FUNCTIONAL ASSESSMENT IN PERSONS WITH NON SEVERE HEMOPHILIA ON PROPHYLAXIS WITH FOCUS ON THOSE WITH 5-YR FOLLOW UP G. Quintavalle1, M.I. Tassoni1, B.M. Roccon1, G.F. Rivolta1, C. Costantino2, R.M. Polo3, A. Matichecchia1, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Az. Ospedaliero-Universitaria di Parma, Italy; 2SSD Riabilitazione Ambulatoriale e Ortogeriatrica, Az. Ospedaliero-Universitaria di Parma, Italy; 3Clinica Ortopedica, Az. Ospedaliero-Universitaria di Parma, Italy
40PDF: 13 -
PO037 | TEMPO: A MOBILE HEALTH APPLICATION FOR PERSONALIZED MANAGEMENT OF HEMOPHILIA R. Gualtierotti1|2, F. Franco3, L. Bedogni4, M. Fassi1, A.A Giachi1, S. Mascetti5, M. Manzoni5, F. Poggi6, M. Pellegrini6, C. Suffritti1, F. Peyvandi1|2 | 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 2Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy; 3Department of Physics, Informatics and Mathematics (FIM), University of Modena and Reggio Emilia, Modena, Italy; 4Department of Sciences and Method for Engineering (DISMI), University of Modena and Reggio Emilia, Modena, Italy; 5Department of Computer Science, Università degli Studi di Milano, Milano, Italy; 6Institute for Cognitive Sciences and Technologies (ISTC), National Research Council (CNR), Bologna, Italy
32PDF: 13 -
PO128 | FROM SEVERE THROMBOSIS TO SUCCESSFUL PREGNANCIES: ORTHOTOPIC LIVER TRANSPLANTATION IN INHERITED AFIBRINOGENEMIA WITH BUDD–CHIARI SYNDROME G. Murante1|2|6, S. Bergonzi1|2|6, M. Capetta1|2|6, F. Valeri1|2, C. Dainese1|2, A. Valpreda4, R. Pastorino1|6, F. Bocchi1|6, R. Romagnoli5, S. Martini3, B. Bruno2|6, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases; 2Division of Hematology; 3SSD Hepatic insufficiency and Liver Transplant; 4Central Lab. Baldi and Riberi; 5General Surgery 2U - Liver Transplant Center, Molinette Hospital, AOU Città della Salute e della Scienza di Torino, Italy; 6Dep. of Molecular Biotechnology and Health Sciences, University of Turin, Italy
21PDF: 10 -
CO-02 | NEONATAL GENOMIC SCREENING ENABLES PRE-SYMPTOMATIC DIAGNOSIS AND PREVENTIVE MANAGEMENT OF HEMOPHILIA B. Borsellino1, B. Pollio1, P. Quarello2|3, T. Martini1, C. Linari4, M. Carabotta5, C. Cagnazzo2, S. Minucci6, F. Fagioli2|3 | 1Paediatric Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital "Città della Salute e della Scienza", Torino, Italy; 2Paediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy; 3Department of Paediatric and Public Health Sciences, University of Turin, Italy; 4Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy; 5Department of Pediatrics, G. d'Annunzio University, Chieti, Italy; 6Italian Institute for Genomic Medicine, IRCCS, Candiolo, Italy
92PDF: 17 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
649PDF: 20 -
CO-17 | EMBODIED SELF-MANAGEMENT IN HEMOPHILIA: PSYCHOSOMATIC EFFECTS OF A SUPERVISED PHYSICAL ACTIVITY PROGRAM F. Valeri1, M. Miniotti2, M.G. Bailon2, C. Dainese1, B. Bruno3, P. Leombruni2, A. Borchiellini1 | 1Regional Centre for Haemorrhagic and Thrombotic Disease, Hematology Division, AOU Città della Salute e della Scienza, Torino, Italy; 2Departement of Neurosciences Rita Levi Montalcini, University of Turin, Italy; 3Division of Hematology, AOU Città della Salute e della Scienza, Department of Molecular Biotechnology and Health sciences, University of Turin, Italy
37PDF: 11 -
PO127 | ANAPHYLACTIC REACTION TO RECOMBINANT ACTIVATED FVII IN A MILD HEMOPHILIA A PATIENT WITH INHIBITOR: A CASE REPORT I. Nichele, G. Carli, G. Marchesini, A. Tosetto | Haematology Department, S. Bortolo Hospital, Vicenza, Italy
19PDF: 11 -
PO05 | Intensive FVIII replacement in haemophilia patients with hypertrophic synovium: a randomized study I.L. Calcaterra1, E. Baldacci2, R. Marino3, F. Valeri4, R.C. Santoro5, G. Pasta6, C. Martinoli7, M. Di Minno1 | 1Department of Clinical Medicine and Surgery, Federico II University, Naples; 2Haematology, University Hospital Policlinico Umberto I, Roma; 3Haemophilia Center and thrombosis, Policlinico, Bari; 4Regional Centre for Haemorrhagic and Thrombotic Diseases, AOU Città Della Salute e Della Scienza; Turin; 5Centre for Hemorrhagic and Thrombotic Disorders, Pugliese Ciaccio Hospital, Catanzaro; 6Fondazione IRCCS San Matteo Hospital, Pavia; 7Department of Health Science DISSAL, University of Genoa, Unit of Radiology and IRCCS San Martino Hospital, Genoa, Italy
600PDF: 17 -
PO69 | Whole blood thrombin generation hypercoagulable profile in a patient with hemolytic crisis due to paroxysmal nocturnal hemoglobinuria: a case report A. Napolitano, L. Spiezia, C. Bulato, E. Campello, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
704PDF: 18 -
CO11 | Oral anticoagulation with vitamin K antagonists in early childhood: a single centre-experience B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
712PDF: 25 -
BEST-10 | CHANGES IN HYPERTROPHIC SYNOVIUM STATUS IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A RECEIVING EMICIZUMAB PROPHYLAXIS: THE RESOLVE STUDY I.L. Calcaterra1, M. Di Minno1, E. Baldacci2, G. D’Errico1, C. Santoro2, A. Strangio3, S. Sorella2, M. Leotta3, R.C. Santoro3 | 1Department of Clinical Medicine and Surgery, Federico II University, Napoli, Italy; 2Haematology, University Hospital Policlinico Umberto I, Roma, Italy; 3Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
88PDF: 17 -
PO22 | Early detection and management of PICC-related thrombosis in oncohematologic patients through serial ultrasound monitoring: a prospective observational study S. Laurenti, M. Schneeberger, G. Rosati, A. Pozzi, M. Padrini, R. Vacchelli, A. Morotti | University of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
648PDF: 27 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
628PDF: 20 -
PO044 | UPDATING MANAGEMENT OF ACQUIRED HEMOPHILIA A USING EMICIZUMAB: REAL-WORLD OUTCOMES BY A COLLABORATIVE NETWORK OF 3 ITALIAN CENTERS MI. Tassoni1, BM. Roccon1, A. Dalla Salda2, R. Benedetti3, R. Rossi4, C. Cattabiani4, G. Quintavalle1, A. Casali2, D. Imberti3, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SOC Medicina Interna per acuti ad indirizzo metabolico ed emocoagulativo, Azienda USL IRCCS Reggio Emilia, Italy; 3Centro Emostasi e Trombosi, Medicina Interna, Azienda USL Piacenza, Italy; 4Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy
24PDF: 8 -
CO002 | RETROSPECTIVE LONGITUDINAL ASSESSMENT OF JOINT HEALTH AND QUALITY OF LIFE IN ADOLESCENT AND ADULT PATIENTS AFFECTED BY MODERATE OR SEVERE HAEMOPHILIA A WITH OR WITHOUT INHIBITOR SWITCHING FROM INTRAVENOUS FVIII TREATMENT TO SUBCUTANEOUS PROPHYLAXIS WITH EMICIZUMAB S. Ceglie1, R. Gualtierotti1|2, S. Arcudi1, A. Ciavarella1, S.M. Siboni1, F. Peyvandi1|2 | 1Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; 2Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milano, Italy
51PDF: 12 -
PO077 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy
22PDF: 7 -
PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA
464PDF: 105 -
PO130 | HEMORRHAGIC AND THROMBOTIC COMPLICATIONS DURING DOACS TREATMENT: THE IMPORTANCE OF A REGULAR AND PROLONGED FOLLOW-UP D. Barcellona1|2, A. Mameli2, S. Cornacchini2, P. Schirru2, L. Fenu2, V. Casu2, F. Marongiu1|2 | 1University of Cagliari, Italy; 2Haemostasis and Thrombosis Unit, Azienda Ospedaliero-Universitaria di Cagliari, Italy
32PDF: 6 -
CO-09 | THE POSSIBLE ROLE OF THE PSYCHOLOGIST IN THE MANAGEMENT OF PATIENTS WITH CONGENITAL BLEEDING DISORDERS: THE EXPERIENCE OF A SINGLE HEMOPHILIA CENTER D. Meneghini1, E. Tosi1, B. Pernice2, L. Del Piccolo2, M. Bodini1, A.C. Giuffrida1 | 1Transfusion Medicine Dep., Integrated University Hospital, Verona, Italy; 2Dep. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
89PDF: 13 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
665PDF: 25 -
PO069 | PERIOPERATIVE CHALLENGES IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING CAPLACIZUMAB TREATMENT J. Agnelli Giacchello1, P. Sciancalepore1, N.F. Trincheri2, L. Contino1, M. Ladetto3, R.M. Santi1 | 1SSD Emostasi e trombosi e malattie rare; 2SC Laboratorio Analisi; 3SCDU Ematologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
22PDF: 8 -
PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE P. Holly1, J. Hudecek1, J. Chudej1, L. Valekova1, I. Plamenova1, E. Flochova1, R. Simonova1, J. Sokol1, J. Stasko1, M. Pietrzykova1|2, E. Vescecikova2 | 1Department of Hematology and Transfusion Medicine, University Hospital in Martin, Martin, Slovakia; 2National Transfusion Service, Martin, Slovakia
520PDF: 103 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
580PDF: 12 -
PO002 | VENOUS THROMBOEMBOLISM IN PATIENTS WITH FACTOR VII DEFICIENCY: A CASE SERIES AND REVIEW OF THE LITERATURE BM. Roccon1, MI. Tassoni1, G. Quintavalle1, F. Riccardi1, A. Matichecchia1, GF. Rivolta1, M. Lombardi3, R. Rossi2, A. Benegiamo2, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Centro Emostasi, UOC Medicina Interna ad indirizzo angiologico e coagulativo, Azienda Ospedaliero-Universitaria di Parma, Italy
26PDF: 11 -
CO-20 | REAL-WORLD EXPERIENCE ON THE MANAGEMENT OF MILD HEAD INJURY IN A COHORT OF CHILDREN WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS TREATED WITH EMICIZUMAB B. Pollio1, B. Borsellino1|2, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
36PDF: 15 -
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
2089PDF: 359SUPPLEMENTARY MATERIAL: 218 -
PO114 | A CASE OF ACQUIRED HEMOPHILIA AFTER TAVI AND CORONARY ANGIOPLASTY IN PATIENT WITH ATRIAL FIBRILLATION AND MULTIPLES CARDIOVASCULAR RISK FACTORS – THE ART AND SCIENCE OF THERAPEUTIC CONFLICT M.M. Poggi1, C. Tamburini2, M. Littera2, M. Mazzetti2 | 1SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy; 2SOD Medicina Interna Interdisciplinare, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
26PDF: 7 -
PO39 | Bleeding events in Von Willebrand disease type 1 yearly treatable with desmopressin A. Gringeri1,2, P.M. Mannucci3, M. Gringeri4, G. Castaman5, F. Peyvandi3,6 | 1Fondazione Charta, Milan; 2Centro di Sanità Solidale, Lucca; 3Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan; 4Department of Medical Biotechnologies and Translational Medicine, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan; 5Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze; 6Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
645PDF: 23 -
CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
644PDF: 15 -
PO129 | CLINICAL BENEFIT OF RECOMBINANT ADAMTS13 IN CTTP ASSOCIATED WITH HOMOZYGOUS PD173G MUTATION AND UNDETECTABLE ACTIVITY M. Sacco1, S. Lancellotti1, M. Basso1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
22PDF: 8 -
CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
44PDF: 16 -
CO-08 | IMPLEMENTING A HUB-AND-SPOKE MODEL FOR HEMOPHILIA DIAGNOSIS AND CARE IN BURKINA FASO THROUGH TRAINING OF “HEALTH ASSISTANTS” C. Gorio1, E. Kafando2, A. Buzzi3 | 1Oncohematology Unit ASST Spedali Civili Brescia, Italy; 2Centre Hospitalier Universitaire Charles de Gaulle, Italy; 3Fondazione Paracelso ETS, Milano, Italy
83PDF: 15 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
492PDF: 116 -
CO066 | COAGULOPATHY IN CAR-T CELL-TREATED PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS: A RETROSPECTIVE, SINGLE-CENTER OBSERVATIONAL STUDY I. Santo1, R. Morganti2, G. Leoni3, G. Tancredi3, L. Contino4, S. Galimberti3, R.M. Santi4, E. Orciuolo5 | 1Azienda Toscana Nord Ovest, Versilia Hospital, Italy; 2Hematology Division AOUP, Pisa, Italy; 3University of Pisa, Hematology Pisa, Italy; 4Azienda Ospedaliera Universitaria Alessandria, Italy; 5Azienda Ospedaliera Universitaria Pisana, Hematology Pisa, Italy
31PDF: 9 -
CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo1, I. Quaglia1, A. Colombo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
45PDF: 16 -
PO80 | Heparin-induced thrombocytopenia: a monocentric experience with danaparoid L. D’Innocenzo, S. Sorrentino, M. De Siati, A. Ferretti, E. De Candia | Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy
702PDF: 13 -
PO113 | A STRANGE CASE OF RECURRENT ISOLATED DIGITAL ARTERIAL THROMBOSIS M.M. Poggi, D. Bruni | SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy
27PDF: 11 -
CO-34 | SIMPLIFIED PERIOPERATIVE MANAGEMENT WITH N8-GP (TUROCTOCOG ALFA PEGOL) IN MAJOR ABDOMINAL SURGERY IN MILD HEMOPHILIA A WITH SEVERE BLEEDING PHENOTYPE: A CASE REPORT J. Di Paolo, R. Malizia, M. Luongo, P. Massaro, M. Di Mascio, S. Verna | Immunohematology Service, ASL 02 Abruzzo, Chieti, Italy
36PDF: 13 -
CO30 | Joint prosthetic surgery in patients with hemophilia A: clinical-functional outcomes and quality of life E. Zanon1, A. Napolitano1, A. Berizzi2, P. Simioni1 | 1Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua; 2Orthopedics and Traumatology Unit, University-Hospital of Padua Medical School, Padua, Italy
695PDF: 33 -
CO-77 | PERINATAL MANAGEMENT IN WOMAN WITH MILD HEMOPHILIA B: A TWIN PREGNANCY CASE T. Martini1, B. Borsellino1|2, B. Pollio1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
40PDF: 14 -
PO058 | IMMUNOMODULATORY EFFECTS OF FOSTAMATINIB IN A PATIENT WITH EVANS SYNDROME, TRIPLE-POSITIVE ANTIPHOSPHOLIPID ANTIBODIES AND RELATED COAGULATION ABNORMALITIES S. Bergonzi1|2|4, G. Murante1|2|4, M. Capetta1|2|4, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|4, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases; 2Division of Hematology; 3Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy; 4Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
22PDF: 10 -
PO07 | Liver transplant in a case of congenital afibrinogenemia G. Murante1,2,3, S. Bergonzi1,2,3, C. Sella1,2,3, F. Valeri1,2, C. Dainese1,2, A. Valpreda4, R. Pastorino1,3, R. Romagnoli5, D. Patrono5, D. Cussa5, S. Martini6, B. Bruno2,3, A. Borchiellini1,2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin; 3Department of Molecular Biotechnology and Health Sciences, University of Turin; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Torino; 5General Surgery 2U - Liver Transplant Center, Molinette Hospital, AOU Città della Salute e della Scienza, Torino; 6SSD Hepatic insufficiency and Liver Transplant, AOU Città della Salute e della Scienza, Torino, Italy
588PDF: 16 -
PO162 | A RARE CASE OF PLATELET DISORDER MIMICKING HEMOPHILIA A M. Shani, T. Goxhaj | Mother Theresa University Hospital, Università Nostra Signora Dell Buon Consiglio, Tirana, Albania
22PDF: 10
